US-licensed Humira

DRUG3 trials

Sponsors

Fresenius Kabi SwissBioSim GmbH, Celltrion, Prestige Biopharma Limited

Conditions

HealthyHealthy SubjectsHealthy Volunteers

Phase 1

MSB11022 in Healthy Subjects

CompletedNCT03014947

Fresenius Kabi SwissBioSim GmbHHealthy Subjects

Start: 2014-05-31End: 2014-12-31Updated: 2019-07-01

To Compare the Pharmacokinetics and Safety of CT-P17 and Humira in Healthy Subjects

CompletedNCT03970824

CelltrionHealthy

Start: 2019-05-31End: 2020-01-15Updated: 2021-11-18

To Compare the Pharmacokinetics and Safety of PBP1502 and Humira in Healthy Subjects

RecruitingNCT05108259

Prestige Biopharma LimitedHealthy Volunteers

Start: 2022-03-30End: 2026-05-31Target: 324Updated: 2025-05-31

Related Papers

Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study.

2021-02-0520 citations

Pharmacokinetic equivalence of CT‐P17 to high‐concentration (100 mg/ml) reference adalimumab: A randomized phase I study in healthy subjects

Clinical and Translational Science2021-01-2716 citations

Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity.

2020-12-0134 citations